Femasys (FEMY)
(Delayed Data from NSDQ)
$1.20 USD
+0.08 (7.14%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $1.18 -0.02 (-1.67%) 6:54 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
Femasys Inc. [FEMY]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Recap: FemaSeed Launch Prep Underway With Expanded Commercial Team
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
FemaSeed Leads to 24% Pregnancy Rate in Severe Infertility Subgroup
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
Strategic Financing to Extend Cash Runway Into 2H25 and Provide Funding For FemaSeed Commercial Launch in Early 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Recap: We Expect FemaSeed Launch Preparations to Initiate Shortly, Followed by Commercialization in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
FemaSeed Approval Clears Path Toward Launch in Early 2024; Increasing PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Recap: FINALE Pivotal Study For FemBloc Has Been Initiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
FemBloc IDE Approved With Pivotal Trial Set to Initiate in 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Recap: FemaSeed Pivotal Data on Track for Mid-2023 and FemBloc IDE Approval Could be Very Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
Noteworthy Discussion Points From Our Meetings at
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Take: Multiple Catalysts Planned for 2023 Including FemBloc Pivotal Study Initiation and FemaSeed Pivotal Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
FemaSeed Focus Is Now On Male Factor Infertility; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
FemCerv Commercial Availability Could Add Additional Near-Term Revenue
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Take: All Timelines Remain on Track; We Expect FemaSeed Interim Data in 4Q22 to Be a Significant Catalyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
FemBloc''s Advantages Could Position It to Be the Preferred Permanent Birth Control Solution
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Take: Focus Remains on 4Q22 FemaSeed Interim Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Take: FemaSeed Interim Data in 4Q22 Could Be a Significant De-Risking Event
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Femasys Inc.
Industry: Medical - Biomedical and Genetics
Two Ends of the Reproductive Health Spectrum, One Device; Initiate at Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
|